• Home
  • 2.0 LPBI Executive Summary
  • 1.0 LPBI Executive Summary
  • Journal PharmaceuticalIntelligence.com
  • Portfolio of IP Assets
  • Knowledge PORTALS System (KPS)
  • 1.0 LPBI – 2012-2020 VISTA
  • LPBI Group’s History
  • 2.0 LPBI – 2021-2025 VISION
  • BioMed e-Series
  • Press Coverage
  • Investor Relations
  • Our TEAM
  • Founder
  • Funding, Deals & Partnerships
  • 1.0 LPBI Group News
  • 1.0 LPBI CALENDAR
  • 2.0 LPBI Group News
  • Testimonials about LPBI
  • DrugDiscovery @LPBI Group
  • Medical 3D Printing
  • e-VOICES Podcasting
  • LPBI Newsletters
  • Customer Surveys
  • Health Care INVESTOR’s Corner ($)
  • 2021 Summer Internship Portal
  • 2021-2025 Medical Text Analysis (NLP)
  • Artificial Intelligence: Genomics & Cancer
  • SOP Web STAT
  • Blockchain Transactions Network Ecosystem
  • Contact Us
  • 1.0 LPBI Brochure
  • 2.0 LPBI Brochure
  • 2.0 LPBI – Calendar of Zooms
  • Coronavirus, SARS-CoV-2 Portal
  • LPBI India
  • Synthetic Biology in Drug Discovery
  • Certificate One Year
  • NFT: Redefined Format of IP Assets
  • Audio English-Spanish: BioMed e-Series
  • Five Bilingual BioMed e-Series
  • Press Releases
  • Intangibles CIM
  • ChatGPT + Wolfram PlugIn
  • Medicine with GPT-4 & ChatGPT
  • BioMed Audio Podcast Library @LPBI Group

Leaders in Pharmaceutical Business Intelligence (LPBI) Group

Funding, Deals & Partnerships: BIOLOGICS & MEDICAL DEVICES; BioMed e-Series; Medicine and Life Sciences Scientific Journal – http://PharmaceuticalIntelligence.com

Feeds:
Posts
Comments

PROTOCOL for Drug Screening of 3rd Party Intellectual Property Presented for Funding Representation

PROTOCOL for Drug Screening of 3rd Party Intellectual Property Presented for Funding Representation

 

Author: Aviva Lev-Ari, PhD, RN

 

This PROTOCOL for LPBI Group’s Presentation of Intellectual Property  for Funding Sourcing comprises of two Investment Opportunity Types:

Type One:

3rd Party IP, i.e., Yossi/Yissum, Yedgar/Yissum, YEDA (Weitzman), T-cube (Technion)

  • We will be on FINDER FEE AGREEMENTS with each party, same terms and conditions across all organizations

Type Two:

Investments in the Joint Venture: LPBI Group + SBH Sciences, Inc. or NewCo

  • Investors assuming an Equity position

We @LPBI Group believe that, presentation of Funding Opportunities to Investors based on the below, described eleven steps process will demonstrate to the Investors the following Business advantages intrinsic to LPBI Group selection process of candidate Drugs for funding:

  1. LPBI Group is an R&D outfit representing a Joint Venture with SBH Sciences, Inc. a US based profitable Biotech with $10Million in Sales that has reached out to GDE for its TEAM of MDs and PhDs to JOINTLY DEVELOP a pipeline of NCE.
  2. LPBI Group is being approached by Third Parties for Funding in 1,2,3 Drug Indications
  3. LPBI Group has an Eleven Steps Process for SCREENING drug candidates in which the TEAM and Dr. Nir are involved in decision making on what New Chemical Entities (NCE) to present to Investors, thus, shortening the Due Diligence to be done by the investors
  4.  The Investors are given CHOICES to channel each DRUG DISCOVERY Project to a direct investor selected by them per “portfolio fit” and past interactions with given Drug Indications and Drug Classes we represent.

1,2,3,4 – will guarantee that our contacts in the Investment Community: NYC, Paris, Europe, Shanghai — will perceive GDE as a WHOLESALE channel with a robust pipeline of Drug Discovery Projects at hand.

 

The Process of Representation of a Third Party for purposes of Funding Sourcing involve the following steps:

  1. The Third Party needs to identify Drug Discovery funding Target opportunities that belong to INDICATIONS 1,2,3, listed, below
  2. These opportunities identified in 1, above, need to be presented to the Team by the Inventor over Skype per our PROCESS of decision making of inclusion for representation to our Investors, aka 

LPBI Group’s PROTOCOL for Drug Screening of 3rd Party Intellectual Property

We defined a process of ELEVEN steps. Our first cycle starts with Dr. Yedgar on 3/7/2016. He presented to the Team in November 2015, first time. This is his second presentation to the Team, 0n 3/8/2016.

Eleven STEPS in the WORKFLOW FOR FUNDING INVOLVEMENT of LPBI Group with Third Parties IP Owners

CASE STUDY: Explorations for funding with Biologics Inventor X

  1. Aviva and Biologics Inventor Xwill meet on ______at 9AM EST, location TBA, optimal at Aviva’s place
  2. GDE’s EAW(s) will arrive to to meet Biologics Inventor X
  3. We will be on Skype for Biologics Inventor XPresentation to the Team from 9AM EST to 10:30AM EST: Mechanism of Actionand all US Patents with time stamp to expiration– Team will receive by e-mail the Presentation in attachment prior to Presentation
  4. Team’s discussion of the Presentation 10:30AM EST to 11:30AM EST
  5. Team’s session adjourn at 11:30AM EST
  6. Biologics Inventor X, EAW(s) and Aviva will continue talking on the Commercialization potential and “How to go about that”

Vegetarian Lunch

Eaw(s) and Biologics Inventor X, Adjourn at 1:30PM EST

Biologics Inventor X and Aviva, adjourn at 2PM EST

 

Our Team activities related to 1 to 6, above – To FOLLOW:

  1.   On ____9AM EST —Eaw(s), Gerard and Aviva will discuss our joint strategy on Skype regarding DRUG DISCOVERY on one or more of the following:

Diabetes

  • Anti-inflamatory
  • Anti-Cancer

as one candidate in the Pipeline of the Joint Venture [may comprise a proposal for three NCE], the other two in the Joint Venture pipeline are Diabetes [Stem cells and Combination drug therapy in Drug-Device] and Anti-Cancer [CAR-T and TCRL]

We will be preparing the

  • Drug Discovery Plan,
  • Drug Delivery Plan

for the Joint Venture or for NewCo to be presented by us to LPBI Groups Investment Partners.

  1.  On ____ Team meeting at 10AM EST: Team will discuss of the Strategy presented by Gerard and Aviva, per discussions with Biologics Inventor X, third component by EAW(s) may be added

Team, please add the____, 9AM to 11:30AM to your Calendar. Please e-mail if you must be absent, otherwise, please attend and participate in the discussion following the Presentation

  1.  Any additional parties, including Joint Venture Partners, please add the ____, 9AM to 1:30PM to your Calendar, visit to Aviva and in person meeting withBiologics Inventor X. Please Confirm your attendance by reply to ALL

Joint Venture Partners, please add ______9AM EST (Strategy discussion with Aviva and Gerard on Skype) and _______10AM EST (Team discussion of Strategy on Skype)

  1.   Third Party IP representative will present to GDE Team, Drug Discoveries Candidates, and the Inventors, that the Representative wishes to present to our Team
  2.  We will decide on inclusion. For example:

D.1   On Diabetes

D.1.1 ours

D.1.2 third party

D.2 On Anti-Inflammatory

D.2.1 ours

D.2.2 third party: Yedgar, Yossi and others

D.3  On Anti-Cancer: we will present to investors

D.3.1 our effort and

D.3.2 the opportunities at Woodland Pharmaceutical and X,Y,Z by third party, inventor and discovery

 

Summary

We @GDE believe that, THAT type of presentation to Investors demonstrate to them the following Business advantages:

  1. GDE is an R&D outfit representing a Joint Venture with SBH Sciences, Inc. a US based profitable Biotech with $10Million in Sales that has reached out to GDE for its TEAM of MDs and PhDs to JOINTLY DEVELOP a pipeline of NCE.
  2. GDE is being approached by Third Parties for Funding in 1,2,3 Drug Indications
  3. GDE has an Eleven Steps Process for SCREENING drug candidates in which the TEAM and Dr. Nir are involved in decision making on what New Chemical Entities (NCE) to present to Investors, thus, shortening the Due Diligence to be done by the investors
  4. The Investors are given CHOICES to channel each DRUG DISCOVERY Project to a direct investor selected by them per “portfolio fit” and past interactions with given Drug Indications and Drug Classes we represent.

1,2,3,4 – will guarantee that our contacts in the Investment Community: NYC, Paris, Europe, Shanghai — will perceive GDE as a WHOLESALE channel with a robust pipeline of Drug Discovery Projects at hand.

Funding will be awarded to:

Type One:

3rd Party IP, i.e., Yossi/Yissum, Yedgar/Yissum, YEDA (Weitzman), T-cube (Technion)

  • We will be on FINDER FEE AGREEMENTS with each party, same terms and conditions

Type Two:

Investments in the Joint Venture:LPBI Group + SBH Sciences, Inc.

  • Investors assuming an Equity position

Share this:

  • Click to share on Twitter (Opens in new window)
  • Click to share on LinkedIn (Opens in new window)
  • Click to share on Facebook (Opens in new window)
  • Click to print (Opens in new window)
  • Click to email a link to a friend (Opens in new window)

Like this:

Like Loading...

  • Follow Blog via Email

    Enter your email address to follow this blog and receive notifications of new posts by email.

    Join 9,318 other subscribers
  • Recent Posts

    • The Continued Impact and Possibilities of AI in Medical and Pharmaceutical Industry Practices September 18, 2023
    • Regulatory T cells (Tregs) are important for sperm tolerance and male fertility September 11, 2023
    • ChatGPT Chemistry Assistant for Text Mining and the Prediction of metal–organic framework (MOF) synthesis August 27, 2023
    • Eight Subcellular Pathologies driving Chronic Metabolic Diseases – Methods for Mapping Bioelectronic Adjustable Measurements as potential new Therapeutics: Impact on Pharmaceuticals in Use August 19, 2023
    • ChatGPT Searches and Advent of Meta Threads: What it Means for Social Media and Science 3.0 July 11, 2023
    • OpenAI and ChatGPT face unique legal challenges over CopyRight Laws July 10, 2023
    • World Medical Innovation Forum, June 12 – June 14, 2023 The Westin Boston Seaport District organized by Mass General Brigham (MGB) June 25, 2023
    • Revolutionizing Business with Apple Vision Pro: The Ultimate Tool for Enhanced Visual Communication June 22, 2023
    • Optimism for Future Equality of Access to Healthcare in the Inaugural address as AMA President, Jesse M. Ehrenfeld, MD, MPH | AMA 2023 Annual Meeting of House of Delegates June 14, 2023
    • The Use of ChatGPT in the World of BioInformatics and Cancer Research and Development of BioGPT by MIT June 12, 2023
  • Archives

  • Categories

  • Meta

    • Log in
    • Entries feed
    • Comments feed
    • WordPress.org
    • 1 2012pharmaceutical
    • 1 Amandeep Kaur
    • 1 Aashir Awan, Phd
    • 1 Abhisar Anand
    • 1 Adina Hazan
    • 1 Alan F. Kaul, PharmD., MS, MBA, FCCP
    • 1 alexcrystal6
    • 1 anamikasarkar
    • 1 apreconasia
    • 1 aptubman
    • 1 aviralvatsa
    • 1 David Orchard-Webb, PhD
    • 1 danutdaagmailcom
    • 1 Demet Sag, Ph.D., CRA, GCP
    • 1 Dror Nir
    • 1 dsmolyar
    • 1 Ethan Coomber
    • 1 evelinacohn
    • 1 FrasonKalapurackal
    • 1 Gail S Thornton
    • 1 Irina Robu
    • 1 jayzmit48
    • 1 jdpmd
    • 1 jshertok
    • 1 kellyperlman
    • 1 Ed Kislauskis
    • 1 larryhbern
    • 1 Madison Davis
    • 1 marzankhan
    • 1 megbaker58
    • 1 ofermar2020
    • 1 Dr. Pati
    • 1 pkandala
    • 1 ritusaxena
    • 1 Rick Mandahl
    • 1 sjwilliamspa
    • 1 Srinivas Sriram
    • 1 stuartlpbi
    • 1 Dr. Sudipta Saha
    • 1 tildabarliya
    • 1 zraviv06
    • 1 zs22

Powered by WordPress.com.

WPThemes.


%d bloggers like this: